Suppr超能文献

州政策与医疗补助管理式医疗中丁丙诺啡处方医生网络的广度。

State Policy and the Breadth of Buprenorphine-Prescriber Networks in Medicaid Managed Care.

机构信息

Johns Hopkins University, Baltimore, MD, USA.

University of Pittsburgh, PA, USA.

出版信息

Med Care Res Rev. 2023 Aug;80(4):423-432. doi: 10.1177/10775587231167514. Epub 2023 Apr 21.

Abstract

Provider networks in Medicaid Managed Care (MMC) play a crucial role in ensuring access to buprenorphine, a highly effective treatment for opioid use disorder. Using a difference-in-differences approach that compares network breadth across provider specialties and market segments within the same state, we investigated the association between three Medicaid policies and the breadth of MMC networks for buprenorphine prescribers: Medicaid expansion, substance use disorder (SUD) network adequacy criteria, and SUD carveouts. We found that both Medicaid expansion and SUD network adequacy criteria were associated with substantially increased breadth in buprenorphine-prescriber networks in MMC. In both cases, we found that the associations were largely driven by increases in the network breadth of primary care physician prescribers. Our findings suggest that Medicaid expansion and SUD network adequacy criteria may be effective strategies at states' disposal to improve access to buprenorphine.

摘要

医疗补助管理式医疗(MMC)中的供应商网络在确保阿片类药物使用障碍的高度有效治疗药物丁丙诺啡的可及性方面发挥着关键作用。我们采用差异中的差异方法,比较了同一州内的供应商专业和市场细分之间的网络广度,研究了三种医疗补助政策与丁丙诺啡处方者 MMC 网络广度之间的关联:医疗补助扩大、物质使用障碍(SUD)网络充足标准和 SUD 除外。我们发现,医疗补助扩大和 SUD 网络充足标准都与 MMC 中丁丙诺啡处方者网络的广度显著增加有关。在这两种情况下,我们发现关联主要是由初级保健医生处方者网络广度的增加驱动的。我们的研究结果表明,医疗补助扩大和 SUD 网络充足标准可能是各州可用来改善丁丙诺啡可及性的有效策略。

相似文献

1
State Policy and the Breadth of Buprenorphine-Prescriber Networks in Medicaid Managed Care.
Med Care Res Rev. 2023 Aug;80(4):423-432. doi: 10.1177/10775587231167514. Epub 2023 Apr 21.
2
Medicaid Managed Care: Access To Primary Care Providers Who Prescribe Buprenorphine.
Health Aff (Millwood). 2022 Jun;41(6):901-910. doi: 10.1377/hlthaff.2021.01719.
3
Composition of buprenorphine prescribing networks in Medicaid and association with quality of care.
J Subst Use Addict Treat. 2024 Aug;163:209363. doi: 10.1016/j.josat.2024.209363. Epub 2024 Apr 18.
4
Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads.
Subst Abus. 2023 Jul;44(3):136-145. doi: 10.1177/08897077231179824. Epub 2023 Jul 4.
5
The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Health Serv Res. 2020 Jun;55(3):383-392. doi: 10.1111/1475-6773.13282. Epub 2020 Mar 12.
6
Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
Subst Abus. 2016;37(1):63-9. doi: 10.1080/08897077.2015.1080208. Epub 2015 Nov 13.
7
A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.
J Subst Abuse Treat. 2019 Sep;104:135-143. doi: 10.1016/j.jsat.2019.06.010. Epub 2019 Jun 15.
8
Medicaid participation among practitioners authorized to prescribe buprenorphine.
J Subst Abuse Treat. 2022 Feb;133:108513. doi: 10.1016/j.jsat.2021.108513. Epub 2021 Jun 1.
9
Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment.
JAMA Health Forum. 2023 May 5;4(5):e231102. doi: 10.1001/jamahealthforum.2023.1102.
10
Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine Treatment.
J Behav Health Serv Res. 2019 Jan;46(1):151-163. doi: 10.1007/s11414-018-9629-4.

引用本文的文献

1
How Specialized Are Special Needs Plans? Evidence From Provider Networks.
Med Care Res Rev. 2025 Feb;82(1):58-67. doi: 10.1177/10775587241296194. Epub 2024 Nov 19.
2
Insurance Instability for Patients With Opioid Use Disorder in the Year After Diagnosis.
JAMA Health Forum. 2024 Jul 5;5(7):e242014. doi: 10.1001/jamahealthforum.2024.2014.
3
Unmet need for mental health care is common across insurance market segments in the United States.
Health Aff Sch. 2024 Mar 8;2(3):qxae032. doi: 10.1093/haschl/qxae032. eCollection 2024 Mar.
4
US payment policy for medications to treat opioid use disorder: landscape and opportunities.
Health Aff Sch. 2024 Feb 27;2(3):qxae024. doi: 10.1093/haschl/qxae024. eCollection 2024 Mar.

本文引用的文献

1
Association Between Medicaid Managed Care Coverage of Substance Use Services and Treatment Utilization.
JAMA Health Forum. 2022 Aug 5;3(8):e222812. doi: 10.1001/jamahealthforum.2022.2812.
2
Physician Network Breadth and Plan Quality Ratings in Medicare Advantage.
JAMA Health Forum. 2021 Jul 30;2(7):e211816. doi: 10.1001/jamahealthforum.2021.1816. eCollection 2021 Jul.
3
Phantom Networks: Discrepancies Between Reported And Realized Mental Health Care Access In Oregon Medicaid.
Health Aff (Millwood). 2022 Jul;41(7):1013-1022. doi: 10.1377/hlthaff.2022.00052.
4
Variation in network adequacy standards in Medicaid managed care.
Am J Manag Care. 2022 Jun;28(6):288-292. doi: 10.37765/ajmc.2022.89156.
5
Medicaid Managed Care: Access To Primary Care Providers Who Prescribe Buprenorphine.
Health Aff (Millwood). 2022 Jun;41(6):901-910. doi: 10.1377/hlthaff.2021.01719.
6
In Medicaid Managed Care Networks, Care Is Highly Concentrated Among A Small Percentage Of Physicians.
Health Aff (Millwood). 2022 May;41(5):760-768. doi: 10.1377/hlthaff.2021.01747.
7
Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the US.
JAMA. 2021 Jun 1;325(21):2206-2208. doi: 10.1001/jama.2021.4469.
8
Changes in Buprenorphine Treatment After Medicaid Expansion.
Psychiatr Serv. 2021 Jun;72(6):633-640. doi: 10.1176/appi.ps.202000491. Epub 2021 Mar 18.
9
Narrow Primary Care Networks in Medicare Advantage.
J Gen Intern Med. 2022 Feb;37(2):488-491. doi: 10.1007/s11606-020-06534-2. Epub 2021 Jan 19.
10
Breadth and Exclusivity of Hospital and Physician Networks in US Insurance Markets.
JAMA Netw Open. 2020 Dec 1;3(12):e2029419. doi: 10.1001/jamanetworkopen.2020.29419.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验